Vanguard Group’s Alder Biopharmaceuticals ALDR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q4 | – | Sell |
-6,537,011
| Closed | -$123M | – | 4196 |
|
|
2019
Q3 | $123M | Sell |
6,537,011
-124,124
| -2% | -$1.42M | ﹤0.01% | 1602 |
|
|
2019
Q2 | $78.4M | Buy |
6,661,135
+111,886
| +2% | +$1.35M | ﹤0.01% | 1880 |
|
|
2019
Q1 | $89.4M | Buy |
6,549,249
+1,284,019
| +24% | +$16.6M | ﹤0.01% | 1807 |
|
|
2018
Q4 | $54M | Buy |
5,265,230
+111,021
| +2% | +$1.42M | ﹤0.01% | 1985 |
|
|
2018
Q3 | $85.8M | Buy |
5,154,209
+115,375
| +2% | +$2.09M | ﹤0.01% | 1878 |
|
|
2018
Q2 | $79.6M | Sell |
5,038,834
-240,441
| -5% | -$3.65M | ﹤0.01% | 1885 |
|
|
2018
Q1 | $67M | Sell |
5,279,275
-79,961
| -1% | -$1.16M | ﹤0.01% | 1917 |
|
|
2017
Q4 | $61.4M | Buy |
5,359,236
+333,659
| +7% | +$3.72M | ﹤0.01% | 1960 |
|
|
2017
Q3 | $61.6M | Buy |
5,025,577
+1,399,004
| +39% | +$14.6M | ﹤0.01% | 1943 |
|
|
2017
Q2 | $41.5M | Buy |
3,626,573
+187,871
| +5% | +$3.47M | ﹤0.01% | 2104 |
|
|
2017
Q1 | $71.5M | Buy |
3,438,702
+194,185
| +6% | +$4.3M | ﹤0.01% | 1825 |
|
|
2016
Q4 | $67.5M | Buy |
3,244,517
+91,369
| +3% | +$2.38M | ﹤0.01% | 1832 |
|
|
2016
Q3 | $103M | Buy |
3,153,148
+60,630
| +2% | +$1.85M | 0.01% | 1539 |
|
|
2016
Q2 | $77.2M | Buy |
3,092,518
+893,334
| +41% | +$24.2M | ﹤0.01% | 1684 |
|
|
2016
Q1 | $53.9M | Buy |
2,199,184
+49,460
| +2% | +$1.15M | ﹤0.01% | 1833 |
|
|
2015
Q4 | $71M | Buy |
2,149,724
+304,556
| +17% | +$10.3M | ﹤0.01% | 1705 |
|
|
2015
Q3 | $60.4M | Buy |
1,845,168
+617,685
| +50% | +$26.3M | ﹤0.01% | 1763 |
|
|
2015
Q2 | $65M | Buy |
1,227,483
+634,874
| +107% | +$23.1M | ﹤0.01% | 1792 |
|
|
2015
Q1 | $17.1M | Buy |
592,609
+358,879
| +154% | +$9.85M | ﹤0.01% | 2391 |
|
|
2014
Q4 | $6.8M | Buy |
233,730
+88,207
| +61% | +$1.58M | ﹤0.01% | 2732 |
|
|
2014
Q3 | $1.84M | Buy |
145,523
+63,384
| +77% | +$958K | ﹤0.01% | 3302 |
|
|
2014
Q2 | $1.65M | Buy |
+82,139
| New | +$1.16M | ﹤0.01% | 3336 |
|
Vanguard Group's ALDR Position: Q4 2019 in Review
Vanguard Group sold out of Alder Biopharmaceuticals (ALDR) in Q4 2019, closing a stake of 6,537,011 shares — an estimated $123M sold.
Vanguard Group first reported a position in ALDR in Q2 2014 and held it in 22 quarters. The position peaked at $123M in Q3 2019. 0 funds tracked by Wall St. Rank hold ALDR as of Q4 2019.
- Vanguard Group reported no remaining Alder Biopharmaceuticals position as of Q4 2019 after selling out during the quarter.
- Vanguard Group sold 6,537,011 Alder Biopharmaceuticals shares in Q4 2019, an estimated $123M.
- Vanguard Group first reported a position in Alder Biopharmaceuticals in Q2 2014 and held it in 22 quarters.
- Vanguard Group's Alder Biopharmaceuticals position peaked at $123M in Q3 2019.
- 0 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q4 2019.
Based on Vanguard Group's 13F filing for Q4 2019, filed 14 Feb 2020.